

Atezolizumab IMpower110

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Atezolizumab IMpower110

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: First-line treatment of patients with high PD-L1 expression  $\geq 50\%$  TC or  $\geq 10\%$  IC and who do not have EGFR mutant or ALK-positive NSCLC  
 Experimental Arm: Atezolizumab  
 Control Arm: Platinum-based chemotherapy

